Pleiotropic effects of incretins

Area of Science:

• Endocrinology
• Pharmacology

Background:

• The incretin system, comprising glucagon-like peptide-1 (GLP-1) and gastric insulinotropic peptide (GIP), plays a crucial role in glucose homeostasis.
• GLP-1 agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors augment this system, offering novel anti-hyperglycemic strategies.
• The GLP-1 receptor's widespread distribution suggests broader physiological roles beyond pancreatic beta-cells.

Purpose of the Study:

• To review the novel anti-hyperglycemic agents that augment the incretin system.
• To explore the pleiotropic effects of incretin-augmenting therapies.
• To summarize the evidence for beneficial effects on cardiovascular, neurological, hepatic, and renal systems.

Main Methods:

• Literature review of studies on GLP-1 agonists and DPP-4 inhibitors.
• Analysis of data on the physiological effects and tissue distribution of incretins.
• Synthesis of evidence regarding the pleiotropic outcomes of incretin-based therapies.

Main Results:

• Incretin-augmenting drugs improve beta-cell function and suppress glucagon, addressing both postprandial and fasting hyperglycemia.
• GLP-1 receptor activation in various tissues indicates systemic effects.
• Therapies show potential benefits including cardiac protection, neuroprotection, improved liver health, insulin sensitivity, weight management, and possible renoprotective effects.

Conclusions:

• Augmenting the incretin system provides a novel therapeutic approach for managing hyperglycemia.
• Incretin-based therapies demonstrate significant pleiotropic effects, extending benefits to multiple organ systems.
• Further research into the full spectrum of incretin system's therapeutic potential is warranted.